OBJECTIVE: Our objective was to investigate the effect of lipid-induced insulin resistance and type 2 diabetes on skeletal muscle calpain-10 mRNA and protein levels. RESEARCH DESIGN AND METHODS: In the first part of this study, 10 healthy subjects underwent hyperinsulinemic euglycemic (4.5 mmol/liter) clamps for 6 h with iv infusion of either saline or a 20% Intralipid emulsion (Fresenius Kabi AG, Bad Homburg, Germany). Skeletal muscle biopsies were taken before and after 3- and 6-h insulin infusion and analyzed for calpain-10 mRNA and protein expression. In the second part of the study, muscle samples obtained after an overnight fast in 10 long-standing, sedentary type 2 diabetes patients, 10 sedentary, weight-matched, normoglycemic controls, and 10 age-matched, endurance-trained cyclists were analyzed for calpain-10 mRNA and protein content. RESULTS: Intralipid infusion in healthy subjects reduced whole body glucose disposal by approximately 50% (P<0.001). Calpain-10 mRNA (P=0.01) but not protein content was reduced after 6-h insulin infusion in both the saline and Intralipid emulsion trials. Skeletal muscle calpain-10 mRNA and protein content did not differ between the type 2 diabetes patients and normoglycemic controls, but there was a strong trend for total calpain-10 protein to be greater in the endurance-trained athletes (P=0.06). CONCLUSIONS: These data indicate that skeletal muscle calpain-10 expression is not modified by insulin resistance per se and suggest that hyperinsulinemia and exercise training may modulate human skeletal muscle calpain-10 expression.
OBJECTIVE: Our objective was to investigate the effect of lipid-induced insulin resistance and type 2 diabetes on skeletal muscle calpain-10 mRNA and protein levels. RESEARCH DESIGN AND METHODS: In the first part of this study, 10 healthy subjects underwent hyperinsulinemic euglycemic (4.5 mmol/liter) clamps for 6 h with iv infusion of either saline or a 20% Intralipid emulsion (Fresenius Kabi AG, Bad Homburg, Germany). Skeletal muscle biopsies were taken before and after 3- and 6-h insulin infusion and analyzed for calpain-10 mRNA and protein expression. In the second part of the study, muscle samples obtained after an overnight fast in 10 long-standing, sedentary type 2 diabetespatients, 10 sedentary, weight-matched, normoglycemic controls, and 10 age-matched, endurance-trained cyclists were analyzed for calpain-10 mRNA and protein content. RESULTS:Intralipid infusion in healthy subjects reduced whole body glucose disposal by approximately 50% (P<0.001). Calpain-10 mRNA (P=0.01) but not protein content was reduced after 6-h insulin infusion in both the saline and Intralipid emulsion trials. Skeletal muscle calpain-10 mRNA and protein content did not differ between the type 2 diabetespatients and normoglycemic controls, but there was a strong trend for total calpain-10 protein to be greater in the endurance-trained athletes (P=0.06). CONCLUSIONS: These data indicate that skeletal muscle calpain-10 expression is not modified by insulin resistance per se and suggest that hyperinsulinemia and exercise training may modulate human skeletal muscle calpain-10 expression.
Authors: S K Sreenan; Y P Zhou; K Otani; P A Hansen; K P Currie; C Y Pan; J P Lee; D M Ostrega; W Pugh; Y Horikawa; N J Cox; C L Hanis; C F Burant; A P Fox; G I Bell; K S Polonsky Journal: Diabetes Date: 2001-09 Impact factor: 9.461
Authors: J C Evans; T M Frayling; P G Cassell; P J Saker; G A Hitman; M Walker; J C Levy; S O'Rahilly; P V Rao; A J Bennett; E C Jones; S Menzel; P Prestwich; N Simecek; M Wishart; R Dhillon; C Fletcher; A Millward; A Demaine; T Wilkin; Y Horikawa; N J Cox; G I Bell; S Ellard; M I McCarthy; A T Hattersley Journal: Am J Hum Genet Date: 2001-07-31 Impact factor: 11.025
Authors: Y Horikawa; N Oda; N J Cox; X Li; M Orho-Melander; M Hara; Y Hinokio; T H Lindner; H Mashima; P E Schwarz; L del Bosque-Plata; Y Horikawa; Y Oda; I Yoshiuchi; S Colilla; K S Polonsky; S Wei; P Concannon; N Iwasaki; J Schulze; L J Baier; C Bogardus; L Groop; E Boerwinkle; C L Hanis; G I Bell Journal: Nat Genet Date: 2000-10 Impact factor: 38.330
Authors: Kostas Tsintzas; Kamal Chokkalingam; Kirsty Jewell; Luke Norton; Ian A Macdonald; Dumitru Constantin-Teodosiu Journal: J Clin Endocrinol Metab Date: 2007-07-24 Impact factor: 5.958
Authors: L Norton; M Fourcaudot; M A Abdul-Ghani; D Winnier; F F Mehta; C P Jenkinson; R A Defronzo Journal: Diabetologia Date: 2011-09-07 Impact factor: 10.122
Authors: María E Sáez; José L González-Sánchez; Reposo Ramírez-Lorca; María T Martínez-Larrad; Carina Zabena; Alejandro González; Francisco J Morón; Agustín Ruiz; Manuel Serrano-Ríos Journal: PLoS One Date: 2008-08-13 Impact factor: 3.240